- İstanbul Florence Nightingale Hospital
- 2020 - 2024 Istanbul Medipol University Hematology Subspecialty Training
- 2017-2019 Dokuz Eylül University Faculty of Medicine Internal Medicine Specialist Training
- 2015-2017 Çukurova University Faculty of Medicine Internal Medicine Specialist Training
- 2008 - 2014 Mustafa Kemal University Faculty of Medicine Medical Education
- 2019-2020 Muş State Hospital Internal Medicine Specialist
- 2014-2015 Canakkale State Hospital General Practitioner
- Turkish Hematology Association
- American Society of Hematology
- European Hematology Association
-
1. Balik Aydin B, Mutlu YG, Sevindik OG. Persistent Polyclonal B-Cell Lymphocytosis
with Binucleated Lymphocytes. Turk J Haematol. 2021;38(2):173-4.
2. Civriz Bozdag S, Cengiz Seval G, Yonal Hindilerden I, Hindilerden F, Andic N, Baydar
M, …. Happy YG,…et al. Clinical Characteristics and Outcomes of COVID-19 in Turkish
Patients with Hematological Malignancies. Turk J Haematol. 2022;39(1):43-54.
3. Sevindik OG, Mergen M, Mergen S, Mutlu YG, Aydin BB, Serin I. To rechallenge or not
to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent
plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient
after a yearlong period of remission. Ann Hematol. 2022;101(11):2545-7.
4. Sevindik OG, Mutlu YG, Aydin BB, Serin I. First-line Usage of Daratumumab,
Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease
Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy,
and Skin Changes Syndrome (CD-POEMS). Hemasphere. 2022;6(7):e728.
5. Yigit Kaya S, Bektas S, Askin AE, Balik Aydin B, Mutlu YG, Sevindik OG.
Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic
hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute
lymphoblastic leukemia patient. Ann Hematol. 2023;102(6):1599-600.
6. Mutlu YG, Aydin BB, Erdogan C, Kizilaslan D, Bekoz HS, Gemici A, et al. Prognostic
Factors and Intensive Care Outcome in Post-Transplant Phase of Hematopoietic Stem
Cell Transplantation: Intensive Care Outcome in Hematopoietic Stem Cell
Transplantation. Indian J Hematol Blood Transfuse. 2023;39(2):167-72.
7. Mutlu YG, Balik Aydin B, Ayaz A, Seca F, Sevindik OG. Mutation profile of the patients
diagnosed with myeloid neoplasia tested with next generation sequencing and clinical
implications. Annals of Medical Research. 2022; 29(4), 406-411.
8. Sadri S., Yönal Hindilerden İ., Mutlu YG., Tiryaki TO, Gemici A. İ., Bekoz HS,
Gökmen Sevindik Ö., Hindilerden F., Kalayoğlu beşışık S., Nalçacı M., Sargın D.
Comparison of different plerixafor-based strategies for adequate hematopoietic stem
cell collection in poor mobilizers. Eur Res J. 2023; 1-12.
9. Mutlu YG, Aydin BB, Cakir A, Canoz O, Erol C, Sevindik OG. Should core needle lymph
node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up
of lymphomas? 2023, Eurasian J Med.
10. Erol VB, Mutlu YG, Aydin BB, Mert A, Sevindik OG. Intravascular B cell lymphoma with
generalized telangiectasias: a rare entity. 2023, J Dtsch Dermatol Ges.
11. Mutlu YG, Sevcik J, Kiss JE, Lister J, Moore LR, Donnenberg AD. Predicting the CD34
content of mobilized peripheral blood leukapheresis products: single institution
experience over 20 years. Cytotherapy. 2023.
12. Mutlu YG, Yigit Kaya S, Maral S, Melek E, Baslar Z, Kaynar L, et al. Relapsed refractory
multiple myeloma with CNS involvement successfully treated with Elranatamab: first
reported case. Front Immunol. 2023;14:1276295.
13. Serin I, Sevindik OG, Balik Aydin B, Melek E, Mutlu YG, Bilgen H, et al. Plerixafor in
autologous stem cell transplantation: Does it affect engraftment kinetics? Transfuse
Apher Sci. 2023;62(6):103809.
14. Askin AE, Bektas S, Serin I, Mutlu YG, Aydin BB, Sevindik OG. Germline CEBPA
Mutation as a Rare Cause of Chronic Neutropenia. Indian J Hematol Blood Transfuse.
2024;40(3):527-30.
15. Sevindik OG, Mutlu YG, Demirkan F. The Contributions of Turkish Hematology to the
Global Literature: A Comparative Analysis. Turk J Haematol. 2025;42(3):246-9.
doi:10.4274/tjh.galenos.2025.2025.0029.
16. Yigit Kaya S, Kaynar L, Mutlu YG, Yildirim M, Serin I, Avci DN et al. Myth or reality:
Graft versus host disease after autologous hematopoietic cell transplantation, a
multicenter experience. Transpl Immunol. 2025;93:102286.
doi:10.1016/j.trim.2025.102286
17. Yigit Kaya S, Melek E, Mutlu YG, Bekoz HS, Maral S, Kaynar L et al. When high dose
methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case
of secondary CNS lymphoma. Ann Hematol. 2025;104(3):2079-80.
doi:10.1007/s00277-025-06285-2.
18. Yigit Kaya S, Mutlu YG, Malkan UY, Mehtap O, Keklik Karadag F, Korkmaz G et al.
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of
relapsed/refractory hairy cell leukemia, a multicenter experience. Leuk Res.
2024;140:107495. doi:10.1016/j.leukres.2024.107495
19. Yigit Kaya S, Mutlu YG, Yucel OK, Nizam Ozen I, Atas U, Melek E et al. Original vs.
Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients.
Indian J Hematol Blood Transfuse. 2025;41(1):38-42. doi:10.1007/s12288-024-01841-8.
20. Mutlu YG, Emre Unsal S, Gulec B, Serin I, Arslan Davulcu E, Sonmez GM et al. The
Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous
Solid Tumor History. Clin Lymphoma Myeloma Leuk. 2025.
doi:10.1016/j.clml.2025.10.006.
21. Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM et al. Effectiveness
of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated
Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients. Am J
Hematol. 2026;101(1):89-96. doi:10.1002/ajh.70142.
Make an Appointment
E-Result
Let Us Call You